ReviewHuman vaccines & immunotherapeutics2021
Early approval of COVID-19 vaccines: Pros and cons.
Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of menstrual alterations following COVID-19 vaccination: systematic review & meta-analysis.BMC women's health · 2024Pooled it
- Evolution of COVID-19 in the State of São Paulo: Analysis of Incidence, Mortality and Lethality from 2020 to 2023.Epidemiologia (Basel, Switzerland) · 2025Article
- Tracking the COVID-19 vaccines: The global landscape.Human vaccines & immunotherapeutics · 2023Review
- Review
- New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention.Materials today. Chemistry · 2023Review
- The Vaccine World of COVID-19: India's Contribution.Vaccines · 2022Review
- A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.Journal of biomedical science · 2022Review
- Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- Long-Term Immunity and Antibody Response: Challenges for Developing Efficient COVID-19 Vaccines.Antibodies (Basel, Switzerland) · 2022Review
- COVID-19 Vaccines: Current and Future Perspectives.Vaccines · 2022Review
- Pill versus vaccine for COVID-19: Is there a genuine dilemma?Ethics, medicine, and public health · 2022Article
- COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development.Microorganisms · 2022Review
- A Review on Measures to Rejuvenate Immune System: Natural Mode of Protection Against Coronavirus Infection.Frontiers in immunology · 2022Review
- Mind the "Vaccine Fatigue".Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of safe and effective vaccines has been an overriding priority for controlling the 2019-coronavirus disease (COVID-19) pandemic. From the onset, COVID-19 has caused high mortality and economic losses and yet has also offered an opportunity to advance novel therapeutics such as DNA and mRNA vaccines. Although it is hoped that the swift acceptance of such vaccines will prevent loss of life, rejuvenate economies and restore normal life, there could also be significant pitfalls. This perspective provides an overview of future directions and challenges in advancing promising vaccine platforms to widespread therapeutic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.